\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThis call is open to scientific leaders in Europe keen to contribute to setting a strategic agenda of research priorities in cancer. This agenda will inform the launch of specific research funding programmes by the Mission on Cancer and will identify use cases to feed the European Federated Cancer Research Data Hub.
To achieve this, experts are encouraged to participate in one or more of the following research areas that have been identified: 1. cancer prevention, 2. early diagnosis, 3. sensitivity and resistance to therapy, 4. pediatric cancer, 5. cancer and ageing, 6. survivorship. Selected participants will be asked to provide input through online questionnaires and will be invited to join a face-to-face meeting in spring 2023, with travel expenses covered by 4.UNCAN.eu.
Interested to join? The necessary information on how to apply can be found here. Deadline for applications is 15 August 2022. Additional information can be found here.
Broader context: The Mission on Cancer Board and the European Beating Cancer Plan launched a pan-European initiative to UNderstand CANcer, UNCAN.eu, with the ultimate goal of “improving the lives of more than 3 million people, living longer and better, by 2030”. In order to define a strategic roadmap for UNCAN.eu, the European Commission has supported the creation of a Coordination and Support Action (CSA), 4.UNCAN.eu, that will identify research programs of priority in translational cancer research.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
On 28 January 2026, the SECURE project has launched a first round of financial support measures to help small businesses achieve compliance with new cybersecurity requirements for their hardware and software products. This will allow micro, small and medium enterprises (MSMEs) to request co-funding to strengthen the cybersecurity of their hardware... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
